Recent developments in chemotherapy for bladder cancer

ONCOLOGY

Volumn 15, Issue 6, 2001, Pages 763-775

  Vaughn, David J ^a,b   Malkowicz, S Bruce ^b  

^a Division of Gynecologic Oncology   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; CARBOPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL; TAXANE; TAXOID; TUMOR MARKER;

ADJUVANT THERAPY; BLADDER TUMOR; HUMAN; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARBOPLATIN; DEOXYCYTIDINE; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0035375768     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001.
2. Sternberg CM, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989.
3. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group study. J Clin Oncol 10:1066-1073, 1992.
4. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990.
5. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988.
6. Seidman AD, Scher H, Gabrilove JL, et al: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial carcinoma. J Clin Oncol 11:408-414, 1993.
7. Loehrer PJ Sr, Elson P, Drecier R, et al: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced bladder carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 12: 483-488, 1994.
8. Logothetis CJ, Finn LD, Smith T, et al: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol 13: 2272-2277, 1995.
9. Sternberg C, de Mulder PH, Schornagel J, et al: Randomized phase III trial in advanced urothelial tract tumors of high dose-intensity M-VAC chemotherapy and G-CSF vs classic M-VAC (abstract). Proc Am Soc Clin Oncol 19:329a, 2000.
10. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome to chemotherapy. J Clin Oncol 17:3173-3181, 1999.
11. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group study. J Clin Oncol 15:2564-2569, 1997.
12. Vogelzang NJ, Stadler WM: Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology 53:243-250, 1999.
13. Pollera CF, Cetibelli A, Crecco M, et al: Weekly gemcitabine in advanced bladder cancer: A preliminary report from phase I study. Ann Oncol 5:182-184, 1994.
14. Lorusso V, Pollera CF, Antimi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 34:1208-1212, 1998.
15. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997.
16. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441-3445, 1997.
17. Von der Masse H, Anderson L, Crino L, et al: A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium (abstract). Proc Am Soc Clin Oncol 16:324a, 1997.
18. Moore MJ, Winquist E, Murray N, et al: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:2876-2881, 1999.
19. Kaufman D, Raghavan D, Carducci M, et al: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921-1927, 2000.